FRX ) is paying $240 million to Merck ( MRK ) for exclusive U.S. rights ..... 166 million it achieved in 2012. Merck , which acquired Saphris through its merger with Schering - Plough in 2009, took $330 million in
Saunders brings a wide range of experience from his CEO position at Bausch & Lomb and his years as an executive at Schering Plough . We think his extensive experience in the pharmaceutical business outside of primary care will actually be a positive
largely based on its average use of capital. The biggest move the company made over the past decade was the acquisition of Schering in 2006, which we view as neutral with the benefits largely equaling the price paid for the company. Further, the acquisition
years, and we particularly applaud the recent addition directors with relevant experience, including Pharmacia and Schering - Plough veteran Carrie Cox and City of Hope CEO Michael Friedman. In addition, we think the firm's acquisition strategy
Stockland SGP raised AUD 400 million of additional equity via an institutional placement at AUD 3.88 per security, representing a 2.5
At the third-quarter update Stockland SGP guided fiscal 2013 earnings per share (EPS) to be down 25% on fiscal 2012. The downgrade to prior guidance for EPS to fall
Stockland's SGP first-half fiscal 2013 normalised operating profit fell by 28% to AUD 255 million, largely due to a change to accounting treatment of interest capitalised into residential development. Stockland also impaired inventory held on balance sheet, resulting in a AUD 318 million writedown ...
Stockland SGP is undertaking a review of its capitalised interest policy following an escalation in the level of capitalised interest on the